Standard
Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma – Authors´ reply. / Fritzsching, Benedikt; Contoli, Marco; Porsbjerg, Celeste; Buchs, Sarah; Larsen, Julie Rask; Elliott, Lisa; Romano, Mercedes; Freemantle, Nick.
In:
The Lancet Regional Health - Europe, Vol. 17, 100388, 2022.
Research output: Contribution to journal › Comment/debate › Research › peer-review
Harvard
Fritzsching, B, Contoli, M
, Porsbjerg, C, Buchs, S, Larsen, JR, Elliott, L, Romano, M & Freemantle, N 2022, '
Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma – Authors´ reply',
The Lancet Regional Health - Europe, vol. 17, 100388.
https://doi.org/10.1016/j.lanepe.2022.100388APA
Fritzsching, B., Contoli, M.
, Porsbjerg, C., Buchs, S., Larsen, J. R., Elliott, L., Romano, M., & Freemantle, N. (2022).
Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma – Authors´ reply.
The Lancet Regional Health - Europe,
17, [100388].
https://doi.org/10.1016/j.lanepe.2022.100388Vancouver
Fritzsching B, Contoli M
, Porsbjerg C, Buchs S, Larsen JR, Elliott L et al.
Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma – Authors´ reply.
The Lancet Regional Health - Europe. 2022;17. 100388.
https://doi.org/10.1016/j.lanepe.2022.100388Author
Fritzsching, Benedikt ; Contoli, Marco ; Porsbjerg, Celeste ; Buchs, Sarah ; Larsen, Julie Rask ; Elliott, Lisa ; Romano, Mercedes ; Freemantle, Nick. / Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma – Authors´ reply. In: The Lancet Regional Health - Europe. 2022 ; Vol. 17.
Bibtex
@article{dbd1062b1b954b9fb9484e1d93a039c5,
title = "Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma – Authors´ reply",
author = "Benedikt Fritzsching and Marco Contoli and Celeste Porsbjerg and Sarah Buchs and Larsen, {Julie Rask} and Lisa Elliott and Mercedes Romano and Nick Freemantle",
note = "Funding Information: Dr. Fritzsching reports personal fees (pertaining travelling to study meeting) from ALK, during the conduct of the study; and personal fees from Novartis and from Merck Sharp & Dohme, outside the submitted work. Dr. Contoli reports personal fees from Alk-Abello, during the conduct of the study; grants, personal fees and non-financial support from Chiesi, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, grants, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees and non-financial support from Zambon, grants from University of Ferrara - Italy, outside the submitted work. Dr. Porsbjerg reports grants from ALK, grants and personal fees from AstraZeneca, grants and personal fees from GSK, grants and personal fees from Novartis, grants and personal fees from Chiesi, grants and personal fees from Sanofi, grants and personal fees from TEVA, outside the submitted work. Sarah Buchs reports to be employed at ALK-Abello. Dr. Rask Larsen reports being an employee at ALK. Dr. Elliott has nothing to disclose. Ms. Romano Rodriguez reports she is an ALK employee. Dr. Freemantle reports personal fees from Astrazeneca, personal fees from Ipsen, personal fees from Sanofi Aventis, personal fees from Novartis, personal fees from Aimmune, personal fees from Vertex, personal fees from Gedeon Richter, personal fees from Galderma, personal fees from Novo Nordisk, outside the submitted work.",
year = "2022",
doi = "10.1016/j.lanepe.2022.100388",
language = "English",
volume = "17",
journal = "The Lancet Regional Health - Europe",
issn = "2666-7762",
publisher = "Elsevier",
}
RIS
TY - JOUR
T1 - Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma – Authors´ reply
AU - Fritzsching, Benedikt
AU - Contoli, Marco
AU - Porsbjerg, Celeste
AU - Buchs, Sarah
AU - Larsen, Julie Rask
AU - Elliott, Lisa
AU - Romano, Mercedes
AU - Freemantle, Nick
N1 - Funding Information:
Dr. Fritzsching reports personal fees (pertaining travelling to study meeting) from ALK, during the conduct of the study; and personal fees from Novartis and from Merck Sharp & Dohme, outside the submitted work. Dr. Contoli reports personal fees from Alk-Abello, during the conduct of the study; grants, personal fees and non-financial support from Chiesi, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, grants, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees and non-financial support from Zambon, grants from University of Ferrara - Italy, outside the submitted work. Dr. Porsbjerg reports grants from ALK, grants and personal fees from AstraZeneca, grants and personal fees from GSK, grants and personal fees from Novartis, grants and personal fees from Chiesi, grants and personal fees from Sanofi, grants and personal fees from TEVA, outside the submitted work. Sarah Buchs reports to be employed at ALK-Abello. Dr. Rask Larsen reports being an employee at ALK. Dr. Elliott has nothing to disclose. Ms. Romano Rodriguez reports she is an ALK employee. Dr. Freemantle reports personal fees from Astrazeneca, personal fees from Ipsen, personal fees from Sanofi Aventis, personal fees from Novartis, personal fees from Aimmune, personal fees from Vertex, personal fees from Gedeon Richter, personal fees from Galderma, personal fees from Novo Nordisk, outside the submitted work.
PY - 2022
Y1 - 2022
U2 - 10.1016/j.lanepe.2022.100388
DO - 10.1016/j.lanepe.2022.100388
M3 - Comment/debate
C2 - 35494214
AN - SCOPUS:85128660802
VL - 17
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
SN - 2666-7762
M1 - 100388
ER -
